RBX-7455 is under clinical development by MikrobEX and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase III drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how RBX-7455’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RBX-7455 overview
RBX-7455 is under development for the prevention of Clostridium difficile infections, hepatic encephalopathy and Crohn's disease. The drug candidate is administered through oral route as a capsule. It constitutes fecal microbiota suspension which contains live microbes. The therapeutic candidate is developed based on microbial restoration therapy (MRT) platform.
MikrobEX overview
Rebiotix Inc (Rebiotix), a subsidiary of Ferring Holding SA, is a clinical stage biotechnology company that develops treatments for debilitating diseases. The company’s pipeline products include RBX2660, RBX7455. Its RBX2660 is available in the form of enema formulation used for the treatment recurrent clostridium difficile infection. Rebiotix’s RBX7455 is an oral formulation in a lyophilized form. The company partners with physicians to evaluate the use of Microbiota Restoration Therapy (MRT) for ulcerative colitis, crohn’s disease, chronic idiopathic constipation, myoclonus dystonia, autism, urea cycle disorders, chronic fatigue syndrome hepatic encephalopathy and multi drug-resistant organisms. Rebiotix is headquartered in Roseville, Minnesota, the US.
For a complete picture of RBX-7455’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
